Myomo Inc (MYO)

$3.435

+0.04

(+1.03%)▲

Live

Insights on Myomo Inc

  • Decreasing Revenue

    Revenue is down for the last 4 quarters, 5.95M → 3.75M (in $), with an average decrease of 14.1% per quarter

  • Decreasing Net Profit

    Netprofit is down for the last 4 quarters, -1.01M → -3.83M (in $), with an average decrease of 59.1% per quarter

  • Vs BSX

    In the last 3 years, Boston Scientific Corp. has given 79.6% return, outperforming this stock by 146.1%

Performance

  • $3.37
    $3.45
    $3.44
    downward going graph

    2.03%

    Downside

    Day's Volatility :2.32%

    Upside

    0.29%

    downward going graph
  • $0.43
    $5.58
    $3.44
    downward going graph

    87.44%

    Downside

    52 Weeks Volatility :92.26%

    Upside

    38.35%

    downward going graph

Returns

PeriodMyomo IncIndex (Russel 2000)
3 Months
-14.36%
0.0%
6 Months
-16.46%
0.0%
1 Year
501.77%
0.0%
3 Years
-66.45%
-22.6%

Highlights

Market Capitalization
100.0M
Book Value
$0.38
Earnings Per Share (EPS)
-0.27
PEG Ratio
0.0
Wall Street Target Price
5.88
Profit Margin
-47.77%
Operating Margin TTM
-103.58%
Return On Assets TTM
-39.04%
Return On Equity TTM
-90.97%
Revenue TTM
19.5M
Revenue Per Share TTM
0.68
Quarterly Revenue Growth YOY
8.9%
Gross Profit TTM
10.3M
EBITDA
-9.3M
Diluted Eps TTM
-0.27
Quarterly Earnings Growth YOY
0.0
EPS Estimate Current Year
-0.24
EPS Estimate Next Year
-0.04
EPS Estimate Current Quarter
-0.1
EPS Estimate Next Quarter
-0.09

Analyst Recommendation

Buy
    88%Buy
    11%Hold
    0
    0%Sell
Based on 9 Wall street analysts offering stock ratings for Myomo Inc(by analysts ranked 0 to 5 stars)
Based on 9 analyst
  • Current
  • 1M Ago
  • 3M Ago
Buy
8
8
8
Hold
1
1
1
Sell
00
00
00

Analyst Forecast

What analysts predicted

Upside of 71.18%

Current $3.44
Target $5.88

Company Financials

FY18Y/Y Change
Revenue
2.4M
↑ 56.79%
Net Income
-10.3M
↓ 14.72%
Net Profit Margin
-422.11%
↑ 353.93%
FY19Y/Y Change
Revenue
3.8M
↑ 57.02%
Net Income
-10.6M
↑ 3.05%
Net Profit Margin
-277.01%
↑ 145.1%
FY20Y/Y Change
Revenue
7.6M
↑ 97.6%
Net Income
-12.0M
↑ 13.24%
Net Profit Margin
-158.75%
↑ 118.26%
FY21Y/Y Change
Revenue
13.9M
↑ 82.72%
Net Income
-10.4M
↓ 13.84%
Net Profit Margin
-74.86%
↑ 83.89%
FY22Y/Y Change
Revenue
15.6M
↑ 12.26%
Net Income
-10.7M
↑ 3.36%
Net Profit Margin
-68.92%
↑ 5.94%
FY23Y/Y Change
Revenue
19.2M
↑ 23.7%
Net Income
-8.1M
↓ 24.0%
Net Profit Margin
-42.34%
↑ 26.58%
Q4 FY22Q/Q Change
Revenue
4.0M
↑ 1.85%
Net Income
-2.2M
↓ 23.4%
Net Profit Margin
-53.63%
↑ 17.68%
Q1 FY23Q/Q Change
Revenue
3.4M
↓ 14.72%
Net Income
-2.6M
↑ 22.0%
Net Profit Margin
-76.72%
↓ 23.09%
Q2 FY23Q/Q Change
Revenue
6.0M
↑ 72.88%
Net Income
-1.0M
↓ 61.65%
Net Profit Margin
-17.02%
↑ 59.7%
Q3 FY23Q/Q Change
Revenue
5.1M
↓ 14.75%
Net Income
-2.0M
↑ 100.07%
Net Profit Margin
-39.95%
↓ 22.93%
Q4 FY23Q/Q Change
Revenue
4.8M
↓ 6.36%
Net Income
-2.5M
↑ 21.25%
Net Profit Margin
-51.72%
↓ 11.77%
Q1 FY24Q/Q Change
Revenue
3.8M
↓ 21.07%
Net Income
-3.8M
↑ 55.91%
Net Profit Margin
-102.16%
↓ 50.44%
FY18Y/Y Change
Total Assets
8.3M
↓ 40.74%
Total Liabilities
1.9M
↑ 21.35%
FY19Y/Y Change
Total Assets
6.6M
↓ 20.32%
Total Liabilities
4.8M
↑ 157.26%
FY20Y/Y Change
Total Assets
14.7M
↑ 122.92%
Total Liabilities
3.1M
↓ 34.13%
FY21Y/Y Change
Total Assets
20.1M
↑ 36.61%
Total Liabilities
4.7M
↑ 49.04%
FY22Y/Y Change
Total Assets
10.2M
↓ 49.43%
Total Liabilities
3.8M
↓ 18.86%
FY23Y/Y Change
Total Assets
14.6M
↑ 43.49%
Total Liabilities
5.6M
↑ 47.06%
Q4 FY22Q/Q Change
Total Assets
10.2M
↓ 16.41%
Total Liabilities
3.8M
↓ 12.28%
Q1 FY23Q/Q Change
Total Assets
13.7M
↑ 35.17%
Total Liabilities
4.1M
↑ 7.93%
Q2 FY23Q/Q Change
Total Assets
13.3M
↓ 3.2%
Total Liabilities
4.5M
↑ 9.08%
Q3 FY23Q/Q Change
Total Assets
17.1M
↑ 28.25%
Total Liabilities
6.0M
↑ 34.71%
Q4 FY23Q/Q Change
Total Assets
14.6M
↓ 14.5%
Total Liabilities
5.6M
↓ 7.27%
Q1 FY24Q/Q Change
Total Assets
16.5M
↑ 13.3%
Total Liabilities
5.6M
↑ 0.52%
FY18Y/Y Change
Operating Cash Flow
-9.6M
↑ 56.11%
Investing Cash Flow
-126.9K
↑ 89.35%
Financing Cash Flow
3.3M
↓ 81.84%
FY19Y/Y Change
Operating Cash Flow
-10.3M
↑ 7.66%
Investing Cash Flow
-52.0K
↓ 59.02%
Financing Cash Flow
8.3M
↑ 149.24%
FY20Y/Y Change
Operating Cash Flow
-9.0M
↓ 12.66%
Investing Cash Flow
-45.8K
↓ 12.0%
Financing Cash Flow
16.8M
↑ 101.73%
FY21Y/Y Change
Operating Cash Flow
-9.5M
↑ 5.7%
Investing Cash Flow
-326.5K
↑ 613.55%
Financing Cash Flow
13.2M
↓ 21.53%
FY22Y/Y Change
Operating Cash Flow
-10.2M
↑ 7.18%
Investing Cash Flow
-310.8K
↓ 4.8%
Financing Cash Flow
376.9K
↓ 97.14%
Q4 FY22Q/Q Change
Operating Cash Flow
-2.5M
↓ 11.95%
Investing Cash Flow
-310.8K
↑ 5318.24%
Financing Cash Flow
376.9K
↑ 0.0%
Q1 FY23Q/Q Change
Operating Cash Flow
-1.8M
↓ 26.28%
Investing Cash Flow
-45.1K
↓ 85.49%
Financing Cash Flow
5.8M
↑ 1431.63%
Q2 FY23Q/Q Change
Operating Cash Flow
-285.5K
↓ 84.28%
Investing Cash Flow
-3.0M
↑ 6572.63%
Financing Cash Flow
-8.1K
↓ 100.14%
Q3 FY23Q/Q Change
Operating Cash Flow
-1.7M
↑ 500.58%
Investing Cash Flow
-4.3M
↑ 43.72%
Financing Cash Flow
3.9M
↓ 48578.16%

Technicals Summary

Sell

Neutral

Buy

Myomo Inc is currently not in a favorable trading position ( SELL ) according to technical analysis indicators.

More on Technical Analysis

Peers

Company Name1 Month6 Month1 Year3 Years5 Years
Myomo Inc
Myomo Inc
-13.71%
-16.46%
501.77%
-66.45%
-87.28%
Stryker Corporation
Stryker Corporation
4.27%
16.65%
22.1%
34.77%
82.03%
Boston Scientific Corp.
Boston Scientific Corp.
4.07%
37.85%
46.89%
79.63%
93.34%
Edwards Lifesciences Corp.
Edwards Lifesciences Corp.
3.26%
27.0%
2.23%
-8.36%
51.45%
Abbott Laboratories
Abbott Laboratories
-2.62%
-2.21%
-0.86%
-5.87%
32.8%
Medtronic Plc
Medtronic Plc
0.44%
2.96%
-1.92%
-33.69%
-13.02%
Company NameP/E RatioP/B RatioPEG RatioEPSROEROADiv YieldBVPS
Myomo Inc
Myomo Inc
NA
NA
0.0
-0.24
-0.91
-0.39
NA
0.38
Stryker Corporation
Stryker Corporation
38.89
38.89
2.92
11.96
0.19
0.07
0.01
50.33
Boston Scientific Corp.
Boston Scientific Corp.
63.5
63.5
1.8
2.33
0.09
0.05
NA
13.56
Edwards Lifesciences Corp.
Edwards Lifesciences Corp.
37.45
37.45
5.19
2.76
0.21
0.12
NA
11.82
Abbott Laboratories
Abbott Laboratories
31.83
31.83
5.99
4.63
0.15
0.06
0.02
22.31
Medtronic Plc
Medtronic Plc
29.48
29.48
1.52
5.2
0.07
0.04
0.03
38.29
Company NameAnalyst ViewMarket Cap5 Years Return %PE RatioProfit Margin
Myomo Inc
Myomo Inc
Buy
$100.0M
-87.28%
NA
-47.77%
Stryker Corporation
Stryker Corporation
Buy
$129.9B
82.03%
38.89
16.03%
Boston Scientific Corp.
Boston Scientific Corp.
Buy
$111.1B
93.34%
63.5
12.05%
Edwards Lifesciences Corp.
Edwards Lifesciences Corp.
Buy
$52.4B
51.45%
37.45
23.01%
Abbott Laboratories
Abbott Laboratories
Buy
$177.8B
32.8%
31.83
13.96%
Medtronic Plc
Medtronic Plc
Buy
$106.7B
-13.02%
29.48
11.36%

Company Information

myomo's mission is to enable individuals to overcome their paralysis by providing innovative, myoelectric orthotics and support services. we are committed to working with healthcare professionals to deliver high quality outcomes and patient satisfaction through research collaborations and continuing education programs. the company empowers persons with a neuromuscular disability to perform functional activities at home, at work, and in the community, resulting in an improved quality of life and lower healthcare costs.

Organization
Myomo Inc
Employees
101
CEO
Mr. Paul R. Gudonis
Industry
Distribution Services

Discover More

FAQs